Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Frank M. Wolf"'
Autor:
Clara Hwang, Monika A. Izano, Michael A. Thompson, Shirish M. Gadgeel, James L. Weese, Tom Mikkelsen, Andrew Schrag, Mahder Teka, Sheetal Walters, Frank M. Wolf, Jonathan Hirsch, Donna R. Rivera, Paul G. Kluetz, Harpreet Singh, Thomas D. Brown
Publikováno v:
Cancer Reports, Vol 4, Iss 5, Pp n/a-n/a (2021)
Abstract Background The understanding of the impact of COVID‐19 in patients with cancer is evolving, with need for rapid analysis. Aims This study aims to compare the clinical and demographic characteristics of patients with cancer (with and withou
Externí odkaz:
https://doaj.org/article/4f55d1001a2b43daa635e599e89b3b58
Autor:
Monika A. Izano, Connor Sweetnam, Chenan Zhang, James L. Weese, Douglas Reding, Jonathan Treisman, Anand Patel, Bindu Potugari, Andrew Stafford, Frank M. Wolf, Mary Tran, Thomas D. Brown, Shirish M. Gadgeel
Publikováno v:
Clinical Lung Cancer. 24:362-365
Autor:
Jeanna Wallenta Law, Hanadi BuAli, Sherri Costa, Michael P. Mullane, Mohamed Hendawi, Michael McPhee, Bryanne Collini, Mahder Teka, Francesca Coutinho, Ronda Broome, Frank M. Wolf, Liz Toland, Trista Weber, Anna Berry, Thomas D. Brown, Haythem Ali
Publikováno v:
Cancer Research. 82:P3-14
Background and Objective: BRCA testing for patients (pts) with triple negative breast cancer (TNBC) is important because it has secondary prevention implications for patients and multigenerational implications allowing for earlier detection of BRCA g
Autor:
Mahder Teka, Monika A Izano, James L. Weese, Tom Mikkelsen, Donna Rivera, Paul G. Kluetz, Sheetal Walters, Clara Hwang, Frank M. Wolf, Harpreet Singh, Shirish M. Gadgeel, Andrew Schrag, Thomas D. Brown, Michael A. Thompson, Jonathan Hirsch
Publikováno v:
Cancer Reports, Vol 4, Iss 5, Pp n/a-n/a (2021)
Cancer Reports
Cancer Reports
Background The understanding of the impact of COVID‐19 in patients with cancer is evolving, with need for rapid analysis. Aims This study aims to compare the clinical and demographic characteristics of patients with cancer (with and without COVID
Autor:
Shirish M. Gadgeel, Tom Mikkelsen, Monika A. Izano, Frank M. Wolf, Thomas D. Brown, Michael A. Thompson, Harpreet Singh, Jonathan Hirsch, James L. Weese, Sheetal Walters, Andrew Schrag, Paul G. Kluetz, Clara Hwang
Publikováno v:
Clinical Cancer Research. 26:S10-02
Introduction: Reports suggest worsened outcomes in patients with cancer (pts) and COVID-19 (Cov), varying by geography and local peak dynamics. We describe characteristics and clinical outcomes of pts with and without Cov. Methods: RWD at 2 Midwester
Autor:
Jeanna Wallenta Law, Zartash Gul, Anna Berry, Michael A. Thompson, Christopher Willner, Sowjanya Vuyyala, Haley McCracken, Katherine Geverd, Frank M. Wolf, Thomas D. Brown, Philip Kuriakose
Publikováno v:
Cancer Research. 82:6259-6259
Background and Objective: Molecular testing and targeted treatments for patients (pts) diagnosed with AML have evolved in recent years. Real-world testing patterns, including next-generation sequencing (NGS), and clinical management of pts with AML w
Publikováno v:
Journal of Clinical Oncology. 40:e21015-e21015
e21015 Background: African American (AA) individuals are disproportionately affected by lung cancer in terms of incidence and mortality, despite lower tobacco exposure compared to Caucasian Americans (CA). Since molecular profiling is critically impo
Autor:
Igor I. Rybkin, Michael A. Thompson, Frank M. Wolf, Kristen Collins, Louisa Laidlaw, Tom Mikkelsen, Jennifer Godden, Mary Walters, James L. Weese, Ronda Broome, Joe Burkhart, Veronica Jones, Chenan Zhang, Thomas D. Brown, Anna Berry
Publikováno v:
Molecular Cancer Therapeutics. 20:P159-P159
Background: Molecular tumor boards (MTB) are a key component of most precision oncology programs, designed to provide a structured multidisciplinary approach to evaluating cancer patients (pts) for therapy (Tx), clinical trial (CT) enrollment, and ge
Autor:
Zartash Gul, Jeanna Wallenta Law, Philip Kuriakose, Michael A. Thompson, Haley McCracken, Sowjanya Vuyyala, Anna B. Berry, Francesca Coutinho, Christopher Willner, Thomas D. Brown, Katherine Geverd, Frank M. Wolf
Publikováno v:
Blood. 138:4443-4443
Background and Objective: Molecular testing and treatment patterns for patients (pts) diagnosed with acute myelogenous leukemia (AML) have evolved over recent years. Next-generation sequencing (NGS) technologies allow for detection of somatic gene al
Autor:
Michael A. Thompson, Luke Peterson, Eyob ale Tadesse, Frank M. Wolf, Thomas D. Brown, Mohamed Hendawi, Kayla Heslin
Publikováno v:
Journal of Clinical Oncology. 39:9105-9105
9105 Background: Immune checkpoint inhibitor (ICI) therapy has become a mainstay of non-small cell lung cancer (NSCLC) treatment. However, not all patients (pts) benefit with a subset paradoxically experiencing accelerated tumor growth while on ICI.